CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: Potential role in vaccine efficacy

AIDS Research and Human Retroviruses

Volumn 15, Issue 5, 1999, Pages 461-470

  Leno, Michel ^a   Carter, Lucretia ^a   Venzon, David J ^a   Romano, Joseph ^b   Markham, Phillip D ^b   Limbach, Keith ^c   Tartaglia, James ^c   Paoletti, Enzo ^c   Benson, John ^a   Franchini, Genoveffa ^a   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^c Virogenetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; HELPER CELL; IMMUNIZATION; POXVIRUS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VACCINATION; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; DISEASE PROGRESSION; IMMUNIZATION SCHEDULE; MACACA MULATTA; RECOMBINANT FUSION PROTEINS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0033586388     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311213     Document Type: Article

References (52)

1. Karzon DT, Bolognesi DP, and Wayne CK: Development of a vaccine for the prevention of AIDS, a critical appraisal. Vaccine 1992;10:1039-1052.
2. Haynes BF: Scientific and social issues of human immunodeficiency virus vaccine development. Science 1993;260:1279-1285.
3. Desrosiers RC: The simian immunodeficiency viruses. Annu Rev Immunol 1993;8:557-578.
4. Daniel MD, Kirchhof F, Czajak SC, Sehgal PK, and Desrosiers RC: Protective effect of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-1941.
5. Almond N, Kent K, Cranage M, Rud E, Clarke B, and Stott FJ: Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995;345:1342-1344.
6. Putkonen P, Walther L, Zhang YJ, Li SL, Nilsson C, Albert J, Biberfeld P, Thorstensson R, and Biberfeld G: Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nature Med 1995;1:914-918.
7. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, and Desrosiers RC: Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 1996;70:3724-3733.
8. Cranage MP, Whatmore AM, Sharpe SA, Cook N, Polyanskaya N, Leech S, Smith JD, Rud EW, Dennis MJ, and Hall GA: Macaques infected with live attenuated SIVmac are protected against super-infection via the rectal mucosa. Virology 1997;229:143-154.
9. Clements JE, Montelaro RC, Zink MC, Amedee AM, Miller S, Trichel AM, Jagerski B, Hauer D, Martin LN, Bohm RP, and Murphey-Corb M: Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 1995;69:2737-2744.
10. mac251: Dependence on route of challenge exposure. J Virol 1998;72:4170-4182.
11. Hu SL, Abrams K, Barber G, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, and Benveniste RE: Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992;255:456-459.
12. Franchini G, Robert-Guroff M, Tartaglia J, Aggarwal A, Abimiku AG, Benson J, Markham P, Limbach K, Hurteau G, Fullen J, Aldrich K, Miller N, Sadoff J, Paoletti E, and Gallo RC: Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. AIDS Res Hum Retroviruses 1995;11:909-920.
13. Abimiku AG, Franchini G, Tartaglia J, Aldrich K, Myagkikh M, Markham P, Chong P, Klein M, Kieny MP, Paoletti E, Gallo RC, and Robert-Guroff M: HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nature Med 1995;1:321-329.
14. Buge SL, Richardson E, Alipanah S, Markham P, Cheng S, Kalyan N, Miller CJ, Lubeck M, Udem S, Eldridge J, and Robert-Guroff M: An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 1997;71:8531-8541.
15. Shafferman A, Jahrling PB, Benveniste RE, Lewis MG, Phipps TJ, Eden-McCutchan F, Sadoff J, Eddy GA, and Burke DS: Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci USA 1991;88:7126-7130.
16. Luke W, Voss G, Stahl-Hennig C, Coulibaly C, Putkonen P, Petry H, and Hunsmann G: Protection of cynomolgus macaques (Macaca fascicularis) against infection with the human immunodeficiency virus type 2 strain ben (HIV-2ben) by immunization with the virion-derived envelope glycoprotein gp130. AIDS Res Hum Retroviruses 1993;9:387-394.
17. Stahl-Hennig C, Coulibaly C, Petry H, Voss G, Dittmer U, Bodemer W, Makoschey B, Jurkiewicz E, Luke W, and Hunsmann G: Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo. AIDS Res Hum Retroviruses 1994;10(Suppl. 2):S27-S32.
18. Lehner T, Wang Y, Cranage M, Bermmeier LA, Mitchell E, Tao L, Hall G, Denis M, Cook N, Brookes R, Klavinskis L, Jones I, Doyle C, and Ward R: Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nature Med 1996;2:767-775.
19. Desrosiers RC, Wyand MS, Kodama T, Ringler DJ, Arthur LO, Sehgal PK, Letvin NL, King NW, and Daniel MD: Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci USA 1989;86:6353-6357.
20. Murphey-Corb M, Martin LN, Davison-Fairburn B, Montelaro RC, Miller M, West M, Ohkawa S, Baskin GB, Zhang JY, Putney SD, Allison AC, and Eppstein DA: A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989;246:1293-1297.
21. Stott EJ: Anti-cell antibody in macaques. Nature (London) 1991; 353:393.
22. Kannagi M, Chalifoux LV, Lord C, and Letvin NL: Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes. J Immunol 1988;140:2237-2242.
23. Walker CM, Moody DJ, Stites DP, and Levy JA: CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-1566.
24. Barker TD, Weissman D, Daucher JA, Roche KM, and Fauci AS: Identification of multiple and distinct CD8+ T cell suppressor activities. J Immunol 1996;156:4476-4483.
25. Wang Y, Tao L, Mitchell E, Bogers WMJM, Coyle C, Bravery CA, Bergmeier LA, Kelly CG, Heeney JL, and Lehner T: Generation of CD8 suppressor factor and β chemokines, induced by xenogenic immunization, in the prevention of simian immunodeficiency virus infection in macaques. Proc Natl Acad Sci USA 1998;95:5223-5228.
26. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, Davis SW, Van Der Hoeven J, Meignier B, Riviere M, Languet B, and Paoletti E: NYVAC: A highly attenuated strain of vaccinia virus. Virology 1992;188:217-232.
27. Daniel MD, Letvin NL, King NW, Kannagi M, Sehgal PK, Hunt RD, Kanki PJ, Essex M, and Desrosiers RC: Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 1985;228: 1201-1204.
28. Romano JW, Gemen V, and Kievits T: NASBA: A novel, isothermal detection technology for qualitative and quantitative HIV-1 RNA measurements. Clin Lab Med 1996;16:89-103.
29. Mackewicz CE, Ortega HW, and Levy JA: CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991;87:1462-1466.
30. Cocchi F, DeVico AL, Garzimo-Demo A, Arya SK, Gallo RC, and Lusso P: Identification of RANTES, MIP-1α and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
31. Baier M, Werner A, Bannert N, Metzner K, and Kurth R: HIV suppression by interleukin-16. Nature (London) 1995;378:563.
32. Mackewicz CE, Levy JA, Cruikshank WW, Kornfeld H, and Center DM: Role of IL-16 in HIV replication. Nature (London) 1996;383:488-489.
33. Mackewicz CE, Barker E, and Levy JA: Role of β-chemokines in suppressing HIV replication. Science 1996;274:1393.
34. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo RC, and DeVico AL: Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 1997;278:695-698.
35. Chen Y and Gupta P: CD8+ T-cell-mediated suppression of HIV-1 infection may not be due to chemokines RANTES, MIP-1α and MIP-1β. AIDS 1996;10:1434-1435.
36. Levy JA, Mackewicz CA, and Barker E: Controlling HIV pathogenesis: The role in the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today 1996;17:217-224.
37. Kootstra NA, Miedema F, and Schuitemaker H: Analysis of CD8+T lymphocyte-mediated nonlytic suppression of autologous and heterologous primary human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1997;13:685-693.
38. Deng H, Unutmaz D, KewalRamani VN, and Littman DR: Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature (London) 1997;388: 296-300.
39. Alkhatib G, Liao F, Berger EA, Farber JM, and Peden KWC: A new SIV co-receptor, STRL33. Nature (London) 1997;388:238.
40. Farzan M, Choe H, Martin K, Marcon L, Hofman W, Karlsson G, Sun Y, Barrett P, Marchand N, Sullivan N, Gerard N, Gerard C, and Sodroski J: Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med 1997;186:405-411.
41. H1 cells. Immunol Today 1993;14:335-338.
42. Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, Dolan MJ, Hendrix CW, Wolf SF, and Shearer GM: Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993;262:1721-1724.
43. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, and Scott P: The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994;263:235-237.
44. Waldmann TA: The IL-2/IL-2 receptor system: A target for rational immune intervention. Immunol Today 1993;14:264-270.
45. Kinter AL, Bende SM, Hardy EC, Jackson R, and Fauci AS: Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci USA 1995;92:10985-10989.
46. Leong KH, Ramsay AJ, Boyle DB, and Ramshaw IA: Selective induction of immune responses by cytokines co-expressed in recombinant fowlpox virus. J Virol 1994;68:8125-8130.
47. Kawakita M, Rao GS, Ritchey JK, Ornstein DK, Hudson MA, Tartaglia J, Paoletti E, Humphrey PA, Harmon TJ, and Ratliff TL: Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst 1997;89: 428-436.
48. Mehrotra PT, Wu D, Crim JA, Mostowski HS, and Siegel JP: Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol 1993;151:2444-2452.
49. Hoffman SL, Crutcher JM, Puri SK, Ansari AA, Villinger F, Franke ED, Singh PP, Finkelman F, Gately MK, Dutta GP, and Sedegah M: Sterile protection of monkeys against malaria after administration of interleukin-12. Nature Med 1997;3:80-83.
50. Vilinger F, Brar SS, Mayne A, Chikkala N, and Ansari AA: Comparative sequence analysis of cytokine genes from human and non-human primates. J Immunol 1995;155:3946-3954.
51. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, Rubin M, Simberkoff MS, and Hamilton JD: Changes in plasma HIV-1 RNA and CD4 lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-431.
52. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, and Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.